Pharmacosmos predicts record financial year after launches in US and China
The intensive investments in the US and China that Pharmacosmos has made over the past few years have been expensive, but now, company leadership expects rewards.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
Pharmacosmos has lit a fire under its dream of becoming an international company by establishing a presence in the US and China through subsidiaries and launching its main product (called Monoferric in the US and Monofer in China) on both markets.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.